Michael Cookson, MD,MHA

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Prokarium
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    10/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pfizer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    10/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pacifice Edge Diagnostics
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    10/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    TesoRx Pharma LLC
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    10/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Bayer Healthcare Pharmaceuticals
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    10/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Myovant Sciences
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    10/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Astellas Pharma, Inc.
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    10/20/2023
Return to Update Series (2023) Lesson 12: Adjuvant and Early Salvage Therapy Recommendations Following Radical Surgery in Urologic Cancers